[go: up one dir, main page]

WO2008135498A3 - Prevention of protein degradation in mammalian cell cultures - Google Patents

Prevention of protein degradation in mammalian cell cultures Download PDF

Info

Publication number
WO2008135498A3
WO2008135498A3 PCT/EP2008/055345 EP2008055345W WO2008135498A3 WO 2008135498 A3 WO2008135498 A3 WO 2008135498A3 EP 2008055345 W EP2008055345 W EP 2008055345W WO 2008135498 A3 WO2008135498 A3 WO 2008135498A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammalian cell
prevention
factor viii
cell cultures
protein degradation
Prior art date
Application number
PCT/EP2008/055345
Other languages
French (fr)
Other versions
WO2008135498A2 (en
Inventor
Henning Ralf Stennicke
Original Assignee
Novo Nordisk As
Henning Ralf Stennicke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Henning Ralf Stennicke filed Critical Novo Nordisk As
Publication of WO2008135498A2 publication Critical patent/WO2008135498A2/en
Publication of WO2008135498A3 publication Critical patent/WO2008135498A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A method for the production of a Factor VIII polypeptide, the method comprising a) culturing a mammalian cell transfected with an expression vector comprising a nucleic acid molecule encoding said Factor VIII polypeptide and expression. control regions operatively linked to thereto, in a cell culture medium under conditions.suitable for expression of said polypeptide; and b) isolating the expressed Factor VIII polypeptide; wherein the cell culture medium in step a) comprises a tissue inhibitor of metalloproteinase (TIMP).
PCT/EP2008/055345 2007-05-04 2008-04-30 Prevention of protein degradation in mammalian cell cultures WO2008135498A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07107476.9 2007-05-04
EP07107476 2007-05-04

Publications (2)

Publication Number Publication Date
WO2008135498A2 WO2008135498A2 (en) 2008-11-13
WO2008135498A3 true WO2008135498A3 (en) 2008-12-31

Family

ID=38521749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055345 WO2008135498A2 (en) 2007-05-04 2008-04-30 Prevention of protein degradation in mammalian cell cultures

Country Status (1)

Country Link
WO (1) WO2008135498A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10759866B2 (en) 2007-07-09 2020-09-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CN101663390B (en) 2006-09-13 2013-10-23 Abbvie公司 Fed-batch cell culture method using hydrolyzate of non-animal origin
CA2738499A1 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
BRPI0920027A2 (en) 2008-10-20 2015-10-06 Abbott Lab isolation and purification of antibodies using protein affinity chromatography
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (en) 2012-09-02 2017-03-21 Abbvie Inc method for controlling protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2022223505A1 (en) 2021-04-19 2022-10-27 Sandoz Ag Control of n-terminal truncation by methionine supplementation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0319944A2 (en) * 1987-12-08 1989-06-14 Zymogenetics, Inc. Co-expression in eukaryotic cells
WO1996015150A1 (en) * 1994-11-14 1996-05-23 Pharmacia & Upjohn Ab Process for purifying factor viii
WO1997043436A1 (en) * 1996-05-14 1997-11-20 Pharmacia & Upjohn Ab A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0319944A2 (en) * 1987-12-08 1989-06-14 Zymogenetics, Inc. Co-expression in eukaryotic cells
WO1996015150A1 (en) * 1994-11-14 1996-05-23 Pharmacia & Upjohn Ab Process for purifying factor viii
WO1997043436A1 (en) * 1996-05-14 1997-11-20 Pharmacia & Upjohn Ab A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARROW R T ET AL: "Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/oorcine factor VIII molecules", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 95, no. 2, 15 January 2000 (2000-01-15), pages 564 - 568, XP002963601, ISSN: 0006-4971 *
BARROW RACHEL T ET AL: "Antigenicity of putative phospholipid membrane-binding residues in factor VIII", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 97, no. 1, 1 January 2001 (2001-01-01), pages 169 - 174, XP002452858, ISSN: 0006-4971 *
ELLIOTT P ET AL: "Protease expression in the supernatant of Chinese Hamster Ovary cells grown in serum-free culture.", BIOTECHNOLOGY LETTERS, vol. 25, no. 22, November 2003 (2003-11-01), pages 1949 - 1952, XP002453337, ISSN: 0141-5492 *
KJALKE MARIANNE ET AL: "Amino acid residues 721-729 are required for full factor VIII activity", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 234, no. 3, 1995, pages 773 - 779, XP002497448, ISSN: 0014-2956 *
MOLS J ET AL: "Recombinant interferon-T secreted by Chinese hamster ovary-320 cells cultivated in suspension in protein-free media is protected against extracellular proteolysis by the expression of natural protease inhibitors and by the addition of plant protein hydrolysates to the culture medium", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, vol. 41, no. 3-4, March 2005 (2005-03-01), pages 83 - 91, XP009090264, ISSN: 1071-2690 *
SANDBERG H ET AL: "Mapping and partial characterization of proteases expressed by a CHO production cell line", BIOTECHNOLOGY AND BIOENGINEERING, vol. 95, no. 5, December 2006 (2006-12-01), pages 961 - 971, XP002453336, ISSN: 0006-3592 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10759866B2 (en) 2007-07-09 2020-09-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US10808037B1 (en) 2007-07-09 2020-10-20 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US10906986B2 (en) 2007-07-09 2021-02-02 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US11078294B2 (en) 2007-07-09 2021-08-03 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US11639395B2 (en) 2007-07-09 2023-05-02 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US11976127B1 (en) 2007-07-09 2024-05-07 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US11987637B1 (en) 2007-07-09 2024-05-21 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US11987638B1 (en) 2007-07-09 2024-05-21 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US11999791B2 (en) 2007-07-09 2024-06-04 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US12098211B2 (en) 2007-07-09 2024-09-24 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US12145997B2 (en) 2007-07-09 2024-11-19 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US12173080B1 (en) 2007-07-09 2024-12-24 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides

Also Published As

Publication number Publication date
WO2008135498A2 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2008135498A3 (en) Prevention of protein degradation in mammalian cell cultures
MX2009011805A (en) Improvement of factor viii polypeptide titers in cell cultures.
NZ598677A (en) Production of proteins in glutamine-free cell culture media
WO2009011258A1 (en) Method for maintaining foreign gene in cell stably
NO20064379L (en) Use of a serum-free cell culture medium for the production of IL-18BP in mammalian cells
WO2008036600A3 (en) Methods of protein production
IL222452B (en) Process for the production of a recombinant polypeptide by culturing mammalian cells in a serum free and protein free cell culture medium
WO2010096588A3 (en) Cell culture media containing combinations of proteins
GB2446525A (en) Stem cell culture medium and method
WO2009028631A1 (en) Agent for promoting corneal endothelial cell adhesion
WO2009086309A3 (en) Cell culture processes
WO2007088372A3 (en) Cell culture
WO2012177619A3 (en) Microorganisms for producing 1,3-butanediol and methods related thereto
WO2010089151A8 (en) Bioreactor for the cultivation of mammalian cells
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
WO2004090096A3 (en) Methods for neural differentiation of embryonic stem cells using protease passaging techniques
WO2009145945A3 (en) Thermophilic and thermoacidophilic metabolism genes and enzymes from alicyclobacillus acidocaldarius and related organisms
EA201001436A1 (en) CELL CONTAINING PENTOUS SUGAR
WO2012052854A3 (en) Plant cell lines and methods of isolating the same
WO2010061187A3 (en) Method for the transformation of plant cell mitochondria
WO2007067564A3 (en) Improved host cells and culture methods
UA92157C2 (en) Process for production of growth hormone
WO2003064630A3 (en) Cell culture medium
DK1897939T3 (en) Microorganism strain for production of recombinant proteins
NZ595833A (en) Method of producing a lipolytic enzyme

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08749927

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08749927

Country of ref document: EP

Kind code of ref document: A2